Target intelligence / Profile preview

Small integral membrane protein 45 (SMIM45)

Target
SMIM45
Molecular classification
Other (not a well-characterized receptor, enzyme, transporter, channel, transcription factor, or typical protein family member)
01

Overview

Small integral membrane protein 45 (SMIM45) is annotated as a protein-coding gene located on human chromosome 22 and is also known by the non-coding RNA symbol LINC00634[1][4][5][8][11]. The gene encodes at least one ultra-conserved 68-amino acid open reading frame (ORF), possibly with functional significance in neuron maturation, though much about its translation and cellular role remains unresolved[2][8][13]. The gene also contains another ORF (107 aa), which may be uniquely human but lacks clear evidence of translation in most tissues[2]. Due to the overlap with non-coding RNA annotation, the gene is sometimes described as a "long intergenic non-protein coding RNA," and the existing data does not support its consideration as a conventional therapeutic target (e.g., receptor, enzyme, transporter)[1][11]. No credible evidence links SMIM45 to direct drug interactions, use as a biomarker, or specific therapeutic safety concerns. Some literature implicates the LINC00634 transcript as an oncogene in certain cancers, but this refers to RNA-level regulatory mechanisms rather than protein function[11]. The gene is inconsistently classified as both a protein-coding gene and a long non-coding RNA (based on aliases and some database entries)[1][5][11]. There is no evidence that SMIM45 is a well-recognized therapeutic target (e.g., classic druggable receptor, enzyme, transporter, or ion channel), nor is it commonly referenced as such in drug discovery or pharmacology resources. Reported biological functions and disease connections are preliminary, mostly limited to transcript-level roles (e.g., in cancer, where the LINC00634 RNA is involved in regulatory networks)[11]. SMIM45 is not a conventional therapeutic target and is not currently considered druggable. Its gene structure and function remain partially characterized, and much of its reported biological significance relates to its RNA rather than as a classical protein target.

Other names
LINC00634BK250D10.8Long intergenic non-protein coding RNA 634Protein SMIM45
02

Mechanism of action

None established

03

Biological functions

Regulation of neuron maturationOther (insufficiently characterized, limited evidence for distinct functional roles)
04

Disease associations

Cancer (as a non-coding RNA, LINC00634 is implicated as an oncogene in esophageal squamous cell carcinoma via the miR-342-3p/Bcl2L1 axis[11])Other (potential associations uncharacterized or speculative)

Beyond the preview

Go deeper on Small integral membrane protein 45 (SMIM45).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Small integral membrane protein 45 (SMIM45).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call